Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study

References

• National Institute of Mental Health. Major Depression [WWW Document]; 2021. Available from: https://www.nimh.nih.gov/health/statistics/major-depression. Accessed December 17, 2021.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM5^®). American Psychiatric Pub; 2013.
   Google Scholar
• Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2(1). doi:10.1038/nrdp.2016.65
   PubMed Web of Science ®Google Scholar
• Druss BG, Hwang I, Petukhova M, et al. Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2009;14:728–737. doi:10.1038/mp.2008.13
   PubMed Web of Science ®Google Scholar
• Kessler RC. The costs of depression. Psyc Clin North Am. 2012;35(1):1–14. doi:10.1016/j.psc.2011.11.005
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus. 2018;16:420–429. doi:10.1176/appi.focus.16407
   PubMedGoogle Scholar
• Olchanski N, Myers MM, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512–522. doi:10.1016/j.clinthera.2012.09.001
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Jackson WC, Rafeyan R, Trivedi MH. Overcoming challenges to treat inadequate response in major depressive disorder. J Clin Psychiatry. 2020;81(3):OT19037BR4. doi:10.4088/JCP.OT19037BR4
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eu Neuropsychopharmacol. 2009;19:34–40. doi:10.1016/j.euroneuro.2008.08.009
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917. doi:10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71:43–64. doi:10.2165/11587620-000000000-00000
   PubMed Web of Science ®Google Scholar
• Eaves S, Rey JA. Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. Pharm Therapeutic. 2016;41:418–422. doi:10.1016/j.schres.2015.01.038
   Google Scholar
• Thase ME, Zhang P, Weiss C, et al. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother. 2019;20(15):1907–1916. doi:10.1080/14656566.2019.1638913
   PubMed Web of Science ®Google Scholar
• Davis LL, Ota A, Perry P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav. 2016;6(10):e00520. doi:10.1002/brb3.520
   PubMed Web of Science ®Google Scholar
• Fava M, Okame T, Matsushima Y, et al. Switching from inadequate adjunctive or combination treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning. Int J Neuropsychopharmacol. 2017;20:22–30. doi:10.1093/ijnp/pyw087
   PubMed Web of Science ®Google Scholar
• Weisler RH, Ota A, Tsuneyoshi K, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affective Disorders. 2016;204(1):40–47. doi:10.1016/j.jad.2016.06.001
   PubMedGoogle Scholar
• Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Focus. 2016;2016(14):244–265. doi:10.1176/appi.focus.140202
   Google Scholar
• Mercieca-Bebber R, King MT, Calvert MJ, et al. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018;9:353–367. doi:10.2147/PROM.S156279
   PubMed Web of Science ®Google Scholar
• Weldring T, Smith SMS. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013;6:61–68. doi:10.4137/HSI.S11093
   PubMedGoogle Scholar
• Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150. doi:10.1176/appi.ajp.163.1.148
   PubMed Web of Science ®Google Scholar
• Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18(1):65–87. doi:10.1016/0165-1781(86)90060-0
   PubMed Web of Science ®Google Scholar
• Bartrés-Faz D, Cattaneo G, Solana J, et al. Meaning in life: resilience beyond reserve. Alzheimers Res Ther. 2018;10:1–10.
   PubMed Web of Science ®Google Scholar
• Ryff CD, Heller AS, Schaefer SM, et al. Purposeful engagement, healthy aging, and the brain. Curr Behav Neurosci Rep. 2016;3(4):318–327. doi:10.1007/s40473-016-0096-z
   PubMedGoogle Scholar
• McIntyre R, Gill H. The Unmet Needs for Major Depressive Disorder. In: Pompili M, McIntyre R, Fiorillo A, Sartoriu N editors. New Directions in Psychiatry. Springer, Cham;2020. doi:10.1007/978-3-030-42637-8_3
   Google Scholar
• Demyttenaere K, Donneau AF, Albert A, Ansseau M, Constant E, Van Heeringen K. What is important in being cured from depression? Discordance between physicians and patients. J Affective Disorders. 2015;174:390–396. doi:10.1016/j.jad.2014.12.004
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Weller E. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. Adv Ther. 2015;10(1):47.
   Google Scholar
• Thase ME, Pedersen AM, Ismail Z, et al. Efficacy of adjunctive brexpiprazole in adults with MDD: improvement of patient engagement based on selected items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) scale. Poster presented at the 32nd Annual Psych Congress, San Diego, California October 3-6, 2019; 2019.
   Google Scholar
• Monti S, Grosso V, Todoerti M, et al. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology. 2018;57:vii54–vii58. doi:10.1093/rheumatology/key109
   PubMed Web of Science ®Google Scholar
• Mukherjee SS, Yu J, Won Y, et al. Natural language processing-based quantification of the Mental State of Psychiatric patients. Computational Psychiatry. 2020;2020(4):76–106. doi:10.1162/cpsy_a_00030
   Google Scholar
• Koita J, Riggio S, Jagoda A. The Mental Status Examination in emergency practice. Emerg Med Clin North Am. 2010;28(3):439–451. doi:10.1016/j.emc.2010.03.008
   PubMed Web of Science ®Google Scholar
• Walker HK, Hall WD, Hurst JW. Clinical Methods: The History, Physical, and Laboratory Examinations. Butterworth-Heinemann; 1990.
   Google Scholar
• Gersing K, Krishnan R. Clinical computing: clinical Management Research Information System (CRIS). Psychiatric Services. 2003;54(9):1199–1200. doi:10.1176/appi.ps.54.9.1199
   PubMed Web of Science ®Google Scholar
• Gersing KR, Krishnan KRR. Practical evidence-based medicine. Psychopharmacol Bull. 2002;36:20–26.
   PubMedGoogle Scholar
• Holmusk. NeuroBlu [WWW Document]. NeuroBlu | by Holmusk; 2020. Available from: https://www.neuroblu.ai/. Accessed July 16, 2021.
   Google Scholar
• Guy W ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
   Google Scholar
• Aas IHM. Global Assessment of Functioning (GAF): properties and frontier of current knowledge. Ann Gen Psychiatry. 2010;9(1):1–10. doi:10.1186/1744-859X-9-20
   Google Scholar
• Lindstrom MJ, Bates DM. Newton—Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Statistical Assoc. 1988;83(404):1014–1022.
   Web of Science ®Google Scholar
• Weiss CA, Meehan SR, Michelle Brown T, et al. Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): analysis of Exit Interviews. Poster presented at the 32nd Annual Psych Congress, San Diego, California October 3-6, 2019; 2019.
   Google Scholar
• Lepola U, Hefting N, Zhang D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability study. Int J Geriatr Psychiatry. 2018;33(10):1403–1410. doi:10.1002/gps.4952
   PubMed Web of Science ®Google Scholar
• Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35:537–555. doi:10.1016/j.neubiorev.2010.06.006
   PubMed Web of Science ®Google Scholar
• Robert P, Lanctôt KL, Agüera-Ortiz L, et al. Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. European Psychiatry. 2018;54:71–76. doi:10.1016/j.eurpsy.2018.07.008
   PubMed Web of Science ®Google Scholar
• Chase TN. Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment. Neurotoxicity Res. 2011;19(2):266–278. doi:10.1007/s12640-010-9196-9
   PubMed Web of Science ®Google Scholar
• Lambert C, Da Silva S, Ceniti AK, et al. Anhedonia in depression and schizophrenia: a transdiagnostic challenge. CNS Neurosci Ther. 2018;24:615–623. doi:10.1111/cns.12854
   PubMed Web of Science ®Google Scholar
• Tayefi M, Ngo P, Chomutare T, et al. Challenges and opportunities beyond structured data in analysis of electronic health records. WIREs Computational Statistics. 2021;13(6):e1549. doi:10.1002/wics.1549
   Web of Science ®Google Scholar
• Perini G, Ramusino MC, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249–1258. doi:10.2147/NDT.S199746
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161–1172. doi:10.1176/ajp.2006.163.7.1161
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D Report. Am J Psychiatry. 2006;163(9):1519–1530. doi:10.1176/ajp.2006.163.9.1519
   PubMed Web of Science ®Google Scholar
• Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126. doi:10.1186/1741-7015-11-126
   PubMed Web of Science ®Google Scholar